Public record
Mounjaro: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Mounjaro by state
State Medicaid programmes paid for 1,415,027 Mounjaro prescriptions in 2025, with $1.51B reimbursed before rebates. California reported the most (233,535), followed by New York (218,864) and Louisiana (103,442); 52 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 1,415,027 | |
| Total reimbursed before rebates, 2025 | $1.51B | |
| States and territories reporting | 52 | with at least one count CMS did not suppress |
| California | 233,535 prescriptions | $247.6M reimbursed |
| New York | 218,864 prescriptions | $237.1M reimbursed |
| Louisiana | 103,442 prescriptions | $108.1M reimbursed |
| Michigan | 66,532 prescriptions | $72.8M reimbursed |
| Kentucky | 63,826 prescriptions | $58.3M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Mounjaro only (brand-name tirzepatide), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Mounjaro
Retail pharmacies paid an average of $538.76 per mL for MOUNJARO 10 MG/0.5 ML PEN as of 2026-11-11, compared with $522.99 twelve months earlier (+3.0%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| MOUNJARO 10 MG/0.5 ML PEN | $538.76 per mL | 12 months earlier $522.99 (+3.0%) |
| MOUNJARO 12.5 MG/0.5 ML PEN | $538.59 per mL | 12 months earlier $522.88 (+3.0%) |
| MOUNJARO 15 MG/0.5 ML PEN | $538.57 per mL | 12 months earlier $522.94 (+3.0%) |
| MOUNJARO 2.5 MG/0.5 ML PEN | $538.75 per mL | 12 months earlier $523.08 (+3.0%) |
| MOUNJARO 5 MG/0.5 ML PEN | $538.70 per mL | 12 months earlier $523.02 (+3.0%) |
| MOUNJARO 7.5 MG/0.5 ML PEN | $538.74 per mL | 12 months earlier $523.03 (+3.0%) |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Mounjaro (brand-name tirzepatide) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Articles on Mounjaro
- Does Aetna (CVS Health) Cover Mounjaro? Prior Authorization, Formulary Tier, and Appeal Steps
- Mounjaro Insurance Coverage, Cost and Alternatives Compared
- Does Humana Cover Mounjaro? Formulary Tiers, Prior Auth, and Appeal Steps
- Does State Medicaid Cover Mounjaro? A State-by-State Breakdown
- Does TRICARE Cover Mounjaro? Formulary, Prior Authorization, and Appeal Steps
- Does UnitedHealthcare Cover Mounjaro? Prior Authorization, Formulary Tier, and Appeal Steps